H.C. Wainwright

La Jolla Pharmaceutical Company (NASDAQ: LJPC) has an upcoming catalyst in the form of a Feb. 28 PDUFA date. An analyst at H.C. Wainwright recommends buying of the shares ahead of the decision.  The Analyst H.C. Wainwright analyst Edward White initiated coverage of the shares of La Jolla...

H.C. Wainwright has initiated bullish coverage of four healthcare stocks headed into the end of 2017. Analyst Edward White explained his positive take on the four stocks in a research note on Thursday. Here’s a rundown of what he had to say. Acceleron Pharma - Buy White said the future of...

It’s been a long road for MannKind Corporation (NASDAQ: MNKD) and its Afrezza inhalable insulin product. However, a generous new FDA label this week may be the light at the end of the tunnel. Here’s a look at inhalable insulin’s long journey and what the new FDA ruling means for...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) investors can breathe a sigh of relief following the latest updates on the company’s Tampa facility, which was the subject of a Complete Response Letter Valeant received from the FDA earlier this month. IN the letter, the FDA pointed out Current...

If investors were to sum up the year 2017 for specialty drug maker RedHill Biopharma Ltd - ADR (NASDAQ: RDHL) in one phrase, it might be this: “catalyst-rich.” A specialty biopharmaceutical company based in Israel, RedHill has a treasure trove of developing drugs in its pipeline to...

Aerie Pharmaceuticals Inc (NASDAQ: AERI) shares were seen up over 29 percent Thursday after the company reported positive Phase III trial data on its glaucoma treatment candidate, Roclatan. According to the company, Roclatan achieved the primary efficacy endpoint in demonstrating superiority over...

Following the results release of an early-stage study of Pennvax-GP, Inovio Pharmaceuticals Inc (NASDAQ: INO)'s HIV vaccine, H.C. Wainwright noted that the vaccine elicited high T-cell and antibody immune responses in healthy and uninfected adults. The Trial Analysts Raghuram Selvaraju and Yi Chen...

Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) announced positive data from a late-stage study of burosumab in adults with X-linked hypophosphatemia. The randomized, double-blind, placebo-controlled study showed that burosumab, or KRN23 demonstrated a statistically significant improvement in serum...

Biopharmx Corp (NYSE: BPMX) shares have moved 38 percent higher in 2017 as the company progresses its dermatology-centric drugs through the pipeline. The Silicon Valley-based pharmaceutical currently has its lead candidate, BPX-01, undergoing both a Phase 2b dose finding trial for the treatment of...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) announced that the read out from its Phase 2 studies for ZYN002, STAR 1 (in epilepsy) and STOP (in osteoarthritis pain), would be available in July or August, with the epilepsy data expected first. H.C. Wainwright’s Corey Davis maintained a Buy...

Ocera Therapeutics Inc (NASDAQ: OCRX)'s lead drug, OCR-002, has “the potential to become the gold standard” for the treatment as well as prevention of overt hepatic encephalopathy in patients with liver cirrhosis, H.C. Wainwright’s Ed Arce said in a report. He initiated coverage...

H.C. Wainwright reiterated its Buy rating on Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) after the company updated on its three P2 clinical programs utilizing ZYN002, its topical gel formulation of cannabidiol (CBD) at its analyst day. The company said all the three programs would now be...

Shares of Ophthotech Corp (NASDAQ: OPHT) tanked more than 80 percent on Monday after the company announced that the primary endpoint in two Phase 3 trials exploring its Fovista® therapy was not met. Fovista is Ophthotech's therapy intended to be administered in combination with an anti VEGF agent...

On September 30, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced Phase 2 results for rinucumab, with the drug not meeting the primary endpoint of the study. On December 12, Ophthotech Corp (NASDAQ: OPHT) announced Phase 3 results for Fovista, which also did not achieve the primary...

H.C. Wainwright reiterated its Buy rating on Kite Pharma Inc (NASDAQ: KITE) on expectations that its cancer drug KTE-C19 would be approved in 2017 given more granular data on hand. “Given that KTE-C19 has demonstrated positive results in DLBCL (including relapsed and refractory subgroups),...